As the total number of confirmed COVID-19 cases surpasses five million in the US, companies across the country are researching potential diagnostic tests, vaccines and treatment options.
This potential application of our cellular therapy comes after the publication of significant results for knee osteoarthritis in American Journal of Sports Medicine; 88% of patients in a multi-site, randomized, placebo-controlled clinical trial responded greater than placebo at one year and reported a median 87% improvement in pain, stiffness and function.
Featured in the Denver Business Journal, our CEO, William Cimino, details how the therapy works. “We isolate between 1.1 million and 1.5 million stromal cells per gram consistently and reliably to create this therapeutic dose,” he said. The stromal vascular cells are isolated from a patient’s own fat tissue and get reimplanted into the patient’s knee.
With 966,000 total knee replacements performed each year, our therapy has the potential to significantly reduce a $200 billion cost burden placed on the U.S. healthcare system and provide patients an alternative to surgery with less cost, pain and recovery time.
Click to read the full article and sign up here to join our community of physicians, scientists, researchers, engineers, providers, payers and patients. Our cellular therapy for knee osteoarthritis is entering a pivotal Phase III trial at Tulane University School of Medicine, Texas Center for Cell Therapy and Research in San Antonio, and New Jersey Regenerative Institute. Other esteemed institutions across the country will be announced soon.